Immunostimulatory properties and enhanced TNF- α mediated cellular immunity for tumor therapy by C60(OH)20 nanoparticles

Nanotechnology

Volumn 20, Issue 41, 2009, Pages

  Liu, Ying ^a   Jiao, Fang ^a   Qiu, Yang ^a   Li, Wei ^a   Qu, Ying ^a   Tian, Chixia ^a   Li, Yufeng ^a   Bai, Ru ^a   Lao, Fang ^a   Zhao, Yuliang ^a   Chai, Zhifang ^a   Chen, Chunying ^b  

^a INSTITUTE OF HIGH ENERGY PHYSICS   (China)

^b NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EFFECT; ANTI-TUMOR ACTIVITIES; BIOLOGICAL ACTIVITIES; CARBON ALLOTROPES; CELL TYPES; CYTOKINES; IMMUNE CELLS; IMMUNE RESPONSE; IMMUNOMODULATORY EFFECTS; IN-VITRO; IN-VIVO; SERUM SAMPLES; SOLUBLE C; T CELLS; T LYMPHOCYTES; TUMOR CELLS; TUMOR THERAPY;

CELL MEMBRANES; MACROPHAGES; TUMORS;

NANOPARTICLES;

FULLERENE DERIVATIVE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CD4 CD8 RATIO; CELL KILLING; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TUMOR CELL; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; LEWIS CARCINOMA; LYMPHOCYTE; METABOLISM; RANDOMIZATION;

ANIMALS; CARCINOMA, LEWIS LUNG; CELLS, CULTURED; FLOW CYTOMETRY; FULLERENES; IMMUNITY, CELLULAR; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-5; LYMPHOCYTES; MACROPHAGES; MICE; MICE, INBRED C57BL; NANOPARTICLES; RANDOM ALLOCATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349656989     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/20/41/415102     Document Type: Article

References (34)

1. Jordan J T, Sun W, Hussain S F, DeAngulo G, Prabhu S S and Heimberger A B 2008 Preferential migration of regulatory T cells mediated by gliomas-ecreted chemokines can be blocked with chemotherapy Cancer Immunol. Immunother. 57 123-31
2. Shankaran V, Ikeda H, Bruce A T, White J M, Swanson P E, Old L J and Schreiber R D 2001 IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 410 1107-11
3. 60: buckminsterfullerene Nature 318 162-3
4. Nel A, Xia T, Mädler L and Li N 2006 Toxic potential of materials at the nanolevel Science 311 622-7
5. 60) induce oxidative stress in the brain of juvenile largemouth bass Environ. Health Perspect. 112 1058-62
6. Yin J J et al 2009 The scavenging of reactive oxygen species and the potential for cell protection by functionalized fullerene materials Biomaterials 30 611-21
7. Yin J J et al 2008 Inhibition of tumor growth by endohedral metallofullerenol nanoparticles optimized as reactive oxygen species scavenger Mol. Pharmacol. 74 1132-40
8. Bosi S, Da R T, Spalluto G and Prato M 2003 Fullerene derivatives: An attractive tool for biological applications Eur. J. Med. Chem. 38 913-23
9. Sayes C M et al 2004 The differential cytotoxicity of water-soluble fullerenes Nano Lett. 4 1881-7
10. Dugan L L, Gabrielsen J K, Yu S P, Lin T S and Choi D W 1996 Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons Neurobiol. Dis. 3 129-35
11. 60, fullerenols, as glutamate receptor antagonists and neuroprotective agents J. Neurosci. Res. 62 600-7
12. Tabata Y, Murakami Y and Ikada Y 1997 Photodynamic effect of polyethylene glycol-modified fullerene on tumor Japan. J. Cancer Res. 88 1108-16 (Pubitemid 28021483)
13. 22 on doxorubicin-induced cytotoxicity Toxicol. In Vitro. 18 629-37
14. 22 ] n nanoparticles: antineoplastic activity of high efficiency and low toxicity Nano Lett. 5 2050-7
15. Melvold R W and Sticca R P 2007 Basic and tumor immunology: a review Surg. Oncol. Clin. North Am. 16 711-35
16. Peek L J, Middaugh C R and Berkland C 2008 Nanotechnology in vaccine delivery Adv. Drug. Deliv. Rev. 60 915-28
17. Dumortier H, Lacotte S, Pastorin G, Marega R, Wu W, Bonifazi D, Briand J P, Prato M, Muller S and Bianco A 2006 Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells Nano Lett. 6 1522-8
18. 60(OH) x Small 4 1168-75
19. Xing G M et al 2004 Influences of structural properties on stability of fullerenols J. Phys. Chem. B 108 11473-9
20. Chiang L Y, Wang L Y, Swirczewski J W, Soled S and Cameron S 1994 Efficient synthesis of polyhydroxylated fullerene derivatives via hydrolysis of polycyclosulfated precursors J. Org. Chem. 59 3960-8
21. Tang J et al 2005 Tuning electronic properties of metallic atom in bondage to a nanospace J. Phys. Chem. B 108 8779-85
22. Li W et al 2008 Translocation of fullerene derivative into lysosome via the pathway of clathrin-mediated endocytosis Nanotechnology 19 145102
23. Maeda N, Kokai Y, Ohtani S, Sahara H, Kumamoto Y Y, Kuriyama I, Hada T, Sato N and Yoshida H 2008 Anti-tumor effect of orally administered spinach glycolipid fraction on implanted cancer cells, colon-26, in mice Lipids 43 741-8
24. Wang J X et al 2006 Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumor-bearing mice Biochem. Pharmacol. 71 872-81
25. Ten H, Timo L M, Van V W, Bakker W and Irma A J M 1996 Isolation and characterization of murine Kupffer cells and splenic macrophages J. Immunol. Methods 193 81-91
26. Martins E J, Ferreira A C, Skorupa A L, Afeche S C, Cipolla-Neto J and Costa Rosa L F 2004 Tryptophan consumption and indoleamines production by peritoneal cavity macrophages J. Leukoc. Biol. 75 1116-21
27. Wang R F, Peng G and Wang H Y 2006 Regulatory T cells and toll-like receptors in tumor immunity Sem. Immunol. 18 136-42
28. Leen A M, Rooney C M and Foster A E 2007 Improving T cell therapy for cancer Annu. Rev. Immunol. 25 243-65
29. Katsikis P D, Wunderlich E S, Smith C A and Herzenberg L A 1995 Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals J. Exp. Med. 181 2029-36
30. Annunziato F, Galli G, Cosmi L, Romagnani P, Manetti R, Maggi E and Romagnani S 1998 Molecules associated with human Th1 or Th2 cells Eur. Cytokine Netw. 9 12-6
31. 22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF- α mediated cellular immunity Biomaterials 30 3934-45
32. Camussi G, Albano E, Tetta C and Bussolino F 1991 The molecular action of tumor necrosis factor-alpha Eur. J. Biochem. 202 3-14
33. Lokshin A, Raskovalova T, Huang X J, Zacharia L C, Jackson E K and Gorelik E 2006 Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells Cancer Res. 66 7758-65
34. Calzascia T, Pellegrini M, Hall H, Sabbagh L, Ono N, Elford A R, Mak T W and Ohashi P S 2007 TNF-α is critical for antitumor but not antiviral T cell immunity in mice J. Clin. Invest. 117 3833-45